Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week

Inclusion Criteria:

• HIV-1 infection, coinfection HIV-1/HIV-2 possible
• Age≥18 years old
• Current dual therapy unchanged for the last 6 months with Dolutegravir/ Lamivudine orDolutegravir / Rilpivirine or Darunavir/r / Lamivudine
• If a genotype is available in the patient medical history; virus must be susceptibleto all on going dual therapy. If no ARN genotype available, the patients can beincluded in the study
• Viral load (VL) < 50 c/mL in the past twelve months, with at least 3 VL measurementsincluding screening; only one blip < 200 c/mL is authorized in the 6-12 previousmonths
• CD4 T cells > 250/mm3 at W-4
• Estimated glomerular filtration rate > 60 mL/min (CKD-EPI method)
• AST et ALT < 3N
• Haemoglobin > 10 g/dL
• Platelets > 100 000/mm3
• For women of childbearing age, negative pregnancy plasmatic test at W-4 and agree touse efficacy contraception during the study
• Commitment to use condom prevention and protection during sexual intercourse for theduration of the trial.
• Social security system coverage (including State Medical Aid-AME, if EC approves it)
• Informed consent form signed

Exclusion Criteria:

• Infection by HIV-2
• Chronic and active Viral B Hepatitis with positive antigen HBs
• Chronic and active Viral C Hepatitis with treatment expected in the next 48 weeks
• Concomitant treatment using interferon, interleukins, any other immune-therapy orchemotherapy, antivitamin K+ with co-treatment by booster
• Concomitant prophylactic or curative treatment for an opportunistic infection
• All conditions (use of alcohol, drugs, etc.) judged by the investigator to possiblyinterfere with study protocol compliance, observance and/or study treatment tolerance
• Pregnant or breast feeding women
• Subjects under "sauvegarde de justice" (judicial protection due to temporarily andslightly diminished mental or physical faculties), or under legal guardianship